Trovagene names new vice president

Friday, February 17, 2012 12:46 PM

Trovagene, a developer of transrenal molecular diagnostics, has named Charlie Rodi, Ph.D., vice president and chief technology officer.

Rodi has held varying positions at GD Searle, Monsanto Genome Sequencing Center, Sequenom and ICx BioSystems, several as vice president or director. He was among the first to use nucleic acid biomarkers in the development of pharmaceuticals, and more recently he established the use of digital PCR in detection of rare alleles in circulating nucleic acids and transcript profiling in circulating tumor cells.

In addition to his expertise and innovation in the detection of nucleic acids, Rodi has been awarded several NIH grants in the area of infectious diseases.

Rodi has been working with the Trovagene leadership team as a consultant since December 2011, and has already contributed greatly to the company’s strategy of mutation detection in the management of cancer and in optimizing the company’s program in HPV detection.

Share:          
CWWeekly

May 21

Parexel consultant testifies on FDA biosimilars guidance

Global Telecom Testing checks ex-U.S. toll-free phone lines for multinational clinical trials

To read the full articles for this issue of CWWeekly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

CWWeekly

May

Newer sites most optimistic about the future
Investigative sites of all sizes, from part-time physician-run sites to large dedicated research centers, report a rebound in operating conditions, according to a new CenterWatch analysis, yet sites from each subgroup indicate they have concerns…

Risk-based monitoring slow to catch on with industry
It's estimated that the cost of physically sending monitors to all investigative sites at regular intervals, a model the industry itself developed and has adhered to for about a decade, eats up one-third to one-half of…

Eye On Millennium
Millennium, The Takeda Oncology Company, discovers and develops novel treatments applying world-class recombinant technology to a wide variety of oncology disease targets…

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

JobWatch centerwatch.com/jobwatch

Featured Jobs